SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Avadel Pharmaceuticals plc (AVDL) , forward earnings yield 3.54%. PEG 1.73.
Criteria proven by this page:
- VALUE (35/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 28.3
- PEG Ratio 1.73 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Analyst consensus target $20.00 (-7.6% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 38/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
35/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AVDL
Valuation Multiples
P/E (TTM)0.0
Forward P/E28.3
PEG Ratio1.73
Forward PEG1.73
P/B Ratio0.00
P/S Ratio12.17
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.51
Forward EPS (Est.)$0.77
Book Value / Share$0.00
Revenue / Share$1.78
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield3.54%
Dividend Yield0.00%
Analyst Target$20.00 (-7.6%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$0.93 |
$173.21M |
$40.66M |
23.5% |
| 2016 |
$-1.00 |
$150.25M |
$-41.28M |
-27.5% |
| 2017 |
$1.61 |
$172.74M |
$67.25M |
38.9% |
| 2018 |
$-2.55 |
$103.27M |
$-95.3M |
-92.3% |
| 2019 |
$-0.89 |
$59.22M |
$-33.23M |
-56.1% |
| 2020 |
$0.13 |
$22.33M |
$7.03M |
31.5% |
| 2021 |
$-1.32 |
$0.00 |
$-77.33M |
- |
| 2022 |
$-2.29 |
$0.00 |
$-137.46M |
- |
| 2023 |
$-2.00 |
$27.96M |
$-160.28M |
-573.2% |
| 2024 |
$-0.51 |
$169.12M |
$-48.83M |
-28.9% |
